2658-6533Research Results in Biomedicine2658-653310.18413/2658-6533-2024-10-2-0-93426Medicine (miscellaneous)<strong>Differential expression of CYP19A1 and lncRNA-CTBP1-AS in the granulosa cells of women with polycystic ovary syndrome</strong><br /> &nbsp;<strong>Differential expression of CYP19A1 and lncRNA-CTBP1-AS in the granulosa cells of women with polycystic ovary syndrome</strong><br /> &nbsp;AliRuba M.AliRuba M.ruba.m.ali@mail.ruLomtevaSvetlana V.LomtevaSvetlana V.embryolab61@gmail.comAleksandrovaAnzhela A.AleksandrovaAnzhela A.aalexsandrova@mail.ruSagamonovaKarina Y.SagamonovaKarina Y.k.sagamonova@mail.ruSagamonovArtur S.SagamonovArtur S.a.sagamonov@gmail.comAmmarManar N.A.AmmarManar N.A.manarammarnour@gmail.comShkuratTatiana P.ShkuratTatiana P.tshkurat@yandex.ru202410200

Background: Hyperandrogenism is the basic indicator of polycystic ovarian syndrome (PCOS) and a key factor in its pathological processes. Patients with PCOS have higher testosterone levels along with a decline in the estradiol/testosterone ratio, which may indicate an aromatase dysfunction. The aim of the study: Investigating the expression levels of CYP19A1 and lncRNA-CTBP1-AS in the granulosa cells (GCs) of women with and without PCOS. Materials and methods: We compared the expression levels of CYP19A1 and lncRNA-CTBP1-AS in granulosa cells from 16 PCOS patients and 20 controls who underwent assisted reproductive technology (ART) treatment at the Center for Human Reproduction and IVF (Rostov-on-Don, Russia) using quantitative real-time PCR. Results: We observed a significant downregulation of CYP19A1 expression in the GCs of PCOS patients, with expression levels approximately 4.7 times lower compared to the control group. Furthermore, we found a positive correlation between CYP19A1 expression and the E2/T ratio in PCOS patients. Conversely, PCOS patients exhibited a remarkable upregulation of CTBP1-AS expression in their GCs, with levels up to 23 times higher than those in the control group. Importantly, we also identified a significant negative correlation between the expression level of CTBP1-AS and CYP19A1 in the GCs of PCOS patients. Conclusion: Our results indicate a potential regulatory role of CTBP1-AS in CYP19A1 expression and suggest its involvement in the pathogenesis of PCOS

Background: Hyperandrogenism is the basic indicator of polycystic ovarian syndrome (PCOS) and a key factor in its pathological processes. Patients with PCOS have higher testosterone levels along with a decline in the estradiol/testosterone ratio, which may indicate an aromatase dysfunction. The aim of the study: Investigating the expression levels of CYP19A1 and lncRNA-CTBP1-AS in the granulosa cells (GCs) of women with and without PCOS. Materials and methods: We compared the expression levels of CYP19A1 and lncRNA-CTBP1-AS in granulosa cells from 16 PCOS patients and 20 controls who underwent assisted reproductive technology (ART) treatment at the Center for Human Reproduction and IVF (Rostov-on-Don, Russia) using quantitative real-time PCR. Results: We observed a significant downregulation of CYP19A1 expression in the GCs of PCOS patients, with expression levels approximately 4.7 times lower compared to the control group. Furthermore, we found a positive correlation between CYP19A1 expression and the E2/T ratio in PCOS patients. Conversely, PCOS patients exhibited a remarkable upregulation of CTBP1-AS expression in their GCs, with levels up to 23 times higher than those in the control group. Importantly, we also identified a significant negative correlation between the expression level of CTBP1-AS and CYP19A1 in the GCs of PCOS patients. Conclusion: Our results indicate a potential regulatory role of CTBP1-AS in CYP19A1 expression and suggest its involvement in the pathogenesis of PCOS

PCOSPolycystic ovarian SyndromeLncRNACYP19A1CTBP1-ASgene expressionPCOSPolycystic ovarian SyndromeLncRNACYP19A1CTBP1-ASgene expressionСписок литературыDeswal R, Narwal V, Dang A, et al. The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. Journal of Human Reproductive Sciences. 2020;13(4):261-271. DOI: https://doi.org/10.4103/jhrs.JHRS_95_18Coll&eacute;e J, Mawet M, Tebache L, et al. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. Gynecological Endocrinology. 2021;37(10):869-874. DOI: https://doi.org/10.1080/09513590.2021.1958310Or&oacute;stica L, Rosas C, Plaza-Parrochia F, et al. Altered Steroid Metabolism and Insulin Signaling in PCOS Endometria: Impact in Tissue Function. Current Pharmaceutical Design. 2016;22(36):5614-5624. DOI: https://doi.org/10.2174/1381612822666160810111528Singh S, Pal N, Shubham S, et al. Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. Journal of Clinical Medicine. 2023;12(4):1454. DOI: https://doi.org/10.3390/jcm12041454Ye W, Xie T, Song Y, et al. The role of androgen and its related signals in PCOS. Journal of cellular and molecular medicine. Journal of Cellular and Molecular Medicine. 2021;25(4):1825-1837. DOI: https://doi.org/10.1111/jcmm.16205Jozkowiak M, Piotrowska-Kempisty H, Kobylarek D, et al. Endocrine Disrupting Chemicals in Polycystic Ovary Syndrome: The Relevant Role of the Theca and Granulosa Cells in the Pathogenesis of the Ovarian Dysfunction. Cells. 2023;12(1):174. DOI: https://doi.org/10.3390/cells12010174Chen J, Shen S, Tan Y, et al. The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome. Journal of ovarian research. Journal of Ovarian Research. 2015;8(1):11. DOI: https://doi.org/10.1186/s13048-015-0139-1Li A, Zhang L, Jiang J, et al. Follicular hyperandrogenism and insulin resistance in polycystic ovary syndrome patients with normal circulating testosterone levels. Journal of Biomedical Research. 2018;32(3):208-214. DOI: https://doi.org/10.7555/JBR.32.20170136Shabbir S, Khurram E, Moorthi VS, et al. The interplay between androgens and the immune response in polycystic ovary syndrome. Journal of Translational Medicine. 2023;21(1):259. DOI: https://doi.org/10.1186/s12967-023-04116-4Lecke SB, Morsch DM, Spritzer PM. CYP19 gene expression in subcutaneous adipose tissue is associated with blood pressure in women with polycystic ovary syndrome. Steroids. 2011;76(12):1383-1388. DOI: https://doi.org/10.1016/j.steroids.2011.07.008Hashemain Z, Amiri-Yekta A, Khosravifar M, et al. CYP19A1 Promoters Activity in Human Granulosa Cells: A Comparison between PCOS and Normal Subjects. Cell Journal. 2022;24(4):170-175. DOI: https://doi.org/10.22074/CELLJ.2022.7787Hinshelwood MM, Mendelson CR. Tissue-specific expression of the human CYP19 (aromatase) gene in ovary and adipose tissue of transgenic mice. Journal of Steroid Biochemistry and Molecular Biology. 2001;79(1-5):193-201. DOI: https://doi.org/10.1016/S0960-0760(01)00157-1Tao S, Hou Y, Diao L, et al. Long noncoding RNA study: Genome-wide approaches. Genes and Diseases. 2023;10(6):2491-2510. DOI: https://doi.org/10.1016/j.gendis.2022.10.024Lim LJ, Jin Y, Yang H, et al. Network of clinically-relevant lncRNAs-mRNAs associated with prognosis of hepatocellular carcinoma patients. Scientific Reports. 2020;10(1):11124. DOI: https://doi.org/10.1038/s41598-020-67742-8Ammar MN, Lipovich L, Shkurat TP, et al. Genetic association of rs564398 polymorphism of the ANRIL long non-coding RNA gene and risk of type 2 diabetes: A meta-analysis. Meta Gene. 2022;31:100997. DOI: https://doi.org/10.1016/j.mgene.2021.100997Sweta S, Dudnakova T, Sudheer S, et al. Importance of Long Non-coding RNAs in the Development and Disease of Skeletal Muscle and Cardiovascular Lineages. Frontiers in Cell and Developmental Biology. 2019;7(2):1-19. DOI: https://doi.org/10.3389/fcell.2019.00228Joshi M, Rajender S. Long non-coding RNAs (lncRNAs) in spermatogenesis and male infertility. Reproductive biology and endocrinology. Reproductive Biology and Endocrinology. 2020;18(1):103. DOI: https://doi.org/10.1186/s12958-020-00660-6Geng J, Cui C, Yin Y, et al. LncRNA NEAT1 affects endometrial receptivity by regulating HOXA10 promoter activity. Cell Cycle. 2022;21(18):1932-1944. DOI: https://doi.org/10.1080/15384101.2022.2075198Huang X, Hao C, Bao H, et al. Aberrant expression of long noncoding RNAs in cumulus cells isolated from PCOS patients. Journal of Assisted Reproduction and Genetics. 2016;33(1):111-121. DOI: https://doi.org/10.1007/s10815-015-0630-zZhu H-L, Chen Y-Q, Zhang Z-F. Downregulation of lncRNA ZFAS1 and upregulation of microRNA-129 repress endocrine disturbance, increase proliferation and inhibit apoptosis of ovarian granulosa cells in polycystic ovarian syndrome by downregulating HMGB1. Genomics. 2020;112(5):3597-3608. DOI: https://doi.org/10.1016/j.ygeno.2020.04.011Yang R, Chen J, Wang L, et al. LncRNA BANCR participates in polycystic ovary syndrome by promoting cell apoptosis. Molecular Medicine Reports. 2019;19(3):1581-1586. DOI: https://doi.org/10.3892/mmr.2018.9793Jing T, Wu Y, Wan A, et al. Circular RNA as a Novel Regulator and Promising Biomarker in Polycystic Ovary Syndrome. Biomolecules. 2023;13(7):1101. DOI: https://doi.org/10.3390/biom13071101Takayama KI, Horie-Inoue K, Katayama S, et al. Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO Journal. 2013;32(12):1665-1680. DOI: https://doi.org/10.1038/emboj.2013.99Massillo C, Dalton GN, Porretti J, et al. CTBP1/CYP19A1/estradiol axis together with adipose tissue impacts over prostate cancer growth associated to metabolic syndrome. International Journal of Cancer. 2019;144(5):1115-1127. DOI: https://doi.org/10.1002/ijc.31773Cui H, Geng CZ. Molecular mechanisms of long chain non-coding RNA CTBP1-AS in regulation of invasion and migration of breast cancer cells. Journal of Biological Regulators and Homeostatic Agents. 2019;33(3):773-786.Puurunen J, Piltonen T, Jaakkola P, et al. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 2009;94(6):1973-1978. DOI: https://doi.org/10.1210/jc.2008-2583Ashraf S, Nabi M, Rasool SuA, et al. Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. Egyptian Journal of Medical Human Genetics. 2019;20:25. DOI: https://doi.org/10.1186/s43042-019-0031-4Panghiyangani R, Soeharso P, Pujianto A, et al. CYP19A1 Gene Expression in Patients with Polycystic Ovarian Syndrome. Journal of Human Reproductive Sciences. 2020;13(2):100-103. DOI: https://doi.org/10.4103/JHRS.JHRS_142_18Agarwal SK, Judd HL, Magoffin DA. A mechanism for the suppression of estrogen production in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 1996;81(10):3686-3691. DOI: https://doi.org/10.1210/jcem.81.10.8855823Hosseini E, Shahhoseini M, Afsharian P, et al. Role of epigenetic modifications in the aberrant CYP19A1 gene expression in polycystic ovary syndrome. Archives of Medical Science. 2019;15(4):887-895. DOI: https://doi.org/10.5114/aoms.2019.86060Che Q, Liu M, Zhang D, et al. Long Noncoding RNA HUPCOS Promotes Follicular Fluid Androgen Excess in PCOS Patients via Aromatase Inhibition. The Journal of clinical endocrinology and metabolism. 2020;105(4):1086-1097 .DOI: 10.1210/CLINEM/DGAA060Liu Z, Hao C, Song D, et al. Androgen Receptor Coregulator CTBP1-AS Is Associated With Polycystic Ovary Syndrome in Chinese Women: A Preliminary Study. Reproductive Sciences. 2015;22(7):829. DOI: https://doi.org/10.1177/1933719114565037Nabi M, Andrabi SM, Rasool SUA, et al. Androgen receptor coregulator long noncoding RNA CTBP1-AS is associated with polycystic ovary syndrome in Kashmiri women. Endocrine. 2021;75(2):614-622. DOI: https://doi.org/10.1007/s12020-021-02894-9